NCT06712030View on ClinicalTrials.gov

Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

June 30, 2027

Conditions
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Interventions
DRUG

Sacubitril / Valsartan

Dose titration of Sacubitril/Valsartán to the maximum tolerated dose (maximum 97/103 mg)

Trial Locations (1)

28222

Hospital Universitario Puerta de Hierro, Majadahonda

All Listed Sponsors
lead

Puerta de Hierro University Hospital

OTHER